Understanding neuropathy in the phase III trial

71% of 229 patients who received ABRAXANE developed any grade sensory neuropathy

Grade 3 peripheral neuropathy in the ABRAXANE arm

Neuropathy in metastatic breast cancer
  • The frequency and severity of sensory neuropathy increased with cumulative dose
    • 3% of patients (7/229) discontinued treatment with ABRAXANE due to sensory neuropathy
    • No Grade 4 sensory neuropathy was reported
  • Only 1 incident of motor neuropathy (Grade 2) was observed in either arm of the controlled trial
Dose modifications

Understanding neuropathy in the phase III trial

71% of 229 patients who received ABRAXANE developed any grade sensory neuropathy

Grade 3 peripheral neuropathy in the ABRAXANE arm

Neuropathy in metastatic breast cancer
  • The frequency and severity of sensory neuropathy increased with cumulative dose
    • 3% of patients (7/229) discontinued treatment with ABRAXANE due to sensory neuropathy
    • No Grade 4 sensory neuropathy was reported
  • Only 1 incident of motor neuropathy (Grade 2) was observed in either arm of the controlled trial
Dose modifications

INDICATION

ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

INDICATION

ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.